Clinical trials
Phase 2/3 Leukemia, Myeloid, Acute trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 4 |
| Terminated | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| AbbVie | 1 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| AstraZeneca | 1 |
| Bellicum Pharmaceuticals | 1 |
| Chimeric Therapies | 1 |
| Gamida Cell -Teva Joint Venture Ltd. | 1 |
| Janssen Research & Development, LLC | 1 |
| Moleculin Biotech, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 16 |
| Myelodysplastic Syndromes | 8 |
| Leukemia | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Anemia, Refractory, with Excess of Blasts | 4 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Leukemia, Myeloid, Accelerated Phase | 3 |
| Leukemia, Myeloid, Chronic-Phase | 3 |
| Anemia, Refractory | 2 |
| Leukemia, Biphenotypic, Acute | 2 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.